Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Michael Swedberg | Drug Discovery and Development | Best Researcher Award

Dr Michael Swedberg, Swedberg Preclinical Partner, Sweden

Dr. Michael Swedberg is a distinguished pharmacologist with extensive expertise in safety pharmacology, CNS pharmacology, gastrointestinal pharmacology, and drug abuse assessment. He has held key leadership roles, including Associate Director at AstraZeneca and founder of Swedberg Preclinical Partner AB. His global impact includes contributions to regulatory compliance, developing novel animal models, and mentoring future researchers. With a Ph.D. in discrimination learning and postdoctoral training at NIDA, Dr. Swedberg has collaborated internationally and received numerous accolades for his innovative research and leadership. His career embodies excellence in pharmacology and preclinical drug discovery. šŸŒšŸ’ŠšŸ”¬

Publication Profile

scopus

Education

Dr. Michael Swedberg is a distinguished academic and researcher, having earned his Ph.D. in 1985 from the University of Uppsala, Sweden. His doctoral dissertation focused on “A Model of Discrimination Learning with Interoceptive Stimuli.” He completed his postdoctoral fellowship at the National Institutes of Health (NIH), specializing in addiction research at the National Institute on Drug Abuse’s Preclinical Pharmacology Branch in Baltimore, Maryland (1985–1988). Additionally, Dr. Swedberg holds a Bachelor of Social Science (B.S.Sc.) from Uppsala University, with a comprehensive background in psychology, sociology, and law. šŸ§ šŸ“ššŸŽ“

Professional Appointments

Dr. Michael Swedberg has had an extensive and distinguished career in pharmacology and drug discovery. From 2014 to 2021, he was the Founder and CEO of Swedberg Preclinical Partner AB in Sweden. Prior to that, he was a Partner and Consultant at The Research Network (TRN) from 2014 to 2016. His earlier career includes key roles at AstraZeneca R&D, where he served as Associate Director in Safety Pharmacology and Preclinical Development. He also held senior leadership positions at Novo Nordisk and Ferrosan. Dr. Swedberg’s journey began as a Lecturer at MƤlardalen University in 1981. šŸ§‘ā€šŸ”¬šŸ’‰šŸ“š

Academic Service

Dr. Michael Swedberg has made significant contributions to the field of pharmacology and neuroscience through various roles. He served as a board member for the Department of Psychology at the University of Uppsala and the Faculty of Social Sciences from 1980 to 1985. His leadership extended to chairing the Council of Graduate Students. Recognized for his service, Dr. Swedberg received awards from the Drug Abuse Liability Ad Hoc Committee and for his work with the Lilly–Novo Nordisk Muscarinic Research Collaboration. He has also been a grant evaluator for the European Union and Poland’s National Centre for Research and Development. šŸŒšŸ”¬šŸ§ 

Presentations

Dr. Michael Swedberg has made significant contributions to the field of drug safety and abuse liability assessment. His research, presented at multiple prestigious meetings, includes the role of drug discrimination studies in evaluating novel compounds’ abuse potential. Notably, his work at the Safety Pharmacology Society, American College of Toxicology, and the Swedish Pharmaceutical Congress has advanced methodologies like rat self-administration and drug discrimination for psychoactive effects. His work on the interaction between mGluR5 antagonists and benzodiazepines also stands out. Swedberg’s contributions to safety pharmacology have had a lasting impact on CNS drug development and regulatory guidelines. šŸ§ šŸ’Š

Lecturing and teaching

Dr. Michael Swedberg has delivered extensive lectures and seminars on safety pharmacology, drug abuse, and CNS risk assessment. His contributions include lectures at the American College of Toxicology, Safety Pharmacology Society, and the European Congress of Toxicologic Pathology, focusing on drug dependence, abuse liability, and CNS safety. Additionally, Swedberg has provided in-depth training on the regulatory and industrial challenges in drug development at AstraZeneca and other global platforms. His teaching spans from the biomedical program at Karolinska Institute to the University of Uppsala, covering neuropharmacology, psychopharmacology, and drug addiction. His educational materials are widely respected in the field. šŸ§ šŸ“ššŸ’Š

Academic Supervision

Dr. Michael Swedberg has mentored numerous students at various stages of their academic careers, including graduate, Ph.D., and postdoctoral researchers. He supervised students at UmeĆ„ University, University of Uppsala, and Karolinska Institute, guiding experimental work in fields such as cannabinoid tolerance, dopamine release, and nicotine’s effects on learning. His postdoctoral supervision included projects on visual and auditory discrimination in drug testing. Swedberg’s research has been supported by multiple prestigious grants, such as the Clas Groschinsky Memorial Foundation and the Swedish Medical Research Council. His contributions have significantly advanced brain and behavior research. šŸŽ“šŸ§ šŸ’”

Committee Service

Dr. Michael Swedberg held several key roles at AstraZeneca, including membership in the Safety Knowledge Group for CNS and leadership in CNS GLP Safety Pharmacology Harmonization. He was also a part of multiple committees, such as the AstraZeneca Expert Advisory Group on Abuse Liability and the Cross Company Abuse Liability Consortium. Dr. Swedberg contributed to international organizations like PhRMA and CPDD, focusing on drug abuse liability. He attended professional courses in safety pharmacology, project management, and leadership, further enhancing his expertise. Additionally, he completed a teaching course at Karolinska Institute, strengthening his academic influence. šŸ§ šŸ’ŠšŸŽ“

Research Focus

Dr. Michael Swedberg’s research focuses on the pharmacology of muscarinic receptors and their potential therapeutic applications, particularly in relation to neurological and psychiatric disorders. His work has delved into muscarinic receptor agonists, with significant contributions to the understanding of their antipsychotic and antinociceptive properties. Additionally, he has explored the role of nicotinic compounds and their reinforcing effects. His research has implications for treating conditions like schizophrenia, Alzheimer’s disease, and irritable bowel syndrome. šŸ§ šŸ”¬šŸ’Š His studies on receptor-ligand interactions and pharmacological profiles contribute to the development of novel drugs for various neurological and gastrointestinal conditions.

Publication Top Notes

Approaches for early identification of abuse potential liability

Drug discrimination: A versatile tool for characterization of CNS safety pharmacology and potential for drug abuse

Drug Discrimination: Use in Preclinical Assessment of Abuse Liability

AZD9272 and AZD2066: Selective and highly central nervous system penetrant mGluR5 antagonists characterized by their discriminative effects

Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839

A multi-site comparison of in vivo safety pharmacology studies conducted to support ICH S7A & B regulatory submissions

Establishment of auditory discrimination and detection of tinnitus induced by salicylic acid and intense tone exposure in the rat

Assoc Prof Dr. Fatemeh Moradian| Drug Discovery and Development |Best Researcher Award

Assoc Prof Dr. Fatemeh Moradian|Drug Discovery and Development|Best Researcher Award

Assoc Prof Dr. Fatemeh Moradian at Sari Agricultural Sciences and Natural Resources University,Iran

PROFILEĀ Ā 

orcid

 

Early Academic Pursuits šŸŽ“

Fatemeh (Elham) Moradian began her academic journey with a B.Sc. in Biology from the University of Shiraz in 1996. Her passion for biochemistry soon led her to pursue further studies at Tarbiat Modares University, where she earned both her M.Sc. in Biochemistry in 2000 and a Ph.D. in Biochemistry in 2006. Her doctoral research, with its focus on enzymology and the intricate biochemical mechanisms involved in living organisms, set the stage for a prolific academic and research career. During this time, she developed expertise in protein structure and function, which later became a cornerstone of her research.

Professional Endeavors šŸ’¼

Following the completion of her Ph.D., Dr. Moradian joined Sari Agricultural Sciences and Natural Resources University (SANRU), where she has been a faculty member from 2006 to 2019. Throughout her tenure, she has taught several advanced courses, including Biochemistry, Enzymology, Biochemistry Mechanisms of Cancer, Animal Cell Culture, and Bioinformatics. Her teaching approach, known for integrating practical applications and research into the curriculum, has shaped many aspiring scientists and biochemists.
Dr. Moradian also had the opportunity to undertake a sabbatical at the University of Alberta in Canada, where she worked at the prestigious Michael James Lab in the Department of Biochemistry. During this 7-month research period (2005-2006), she contributed to a project focused on the structural genomics of Mycobacterium tuberculosis, honing her expertise in microbial biochemistry and structural analysis.

Contributions and Research Focus šŸ”¬

Dr. Moradian’s research interests span a wide array of biochemistry-related fields, but her core focus lies in enzymology, protein purification, cancer research, and microbial biochemistry. Her research on the isolation, purification, and characterization of novel enzymes has made significant contributions to both environmental and medical biotechnology. One of her early landmark studies involved the isolation and characterization of an alkaline protease from Bacillus sp HS-08, which was presented at the International Conference on Environmental, Industrial, and Applied Microbiology in Spain in 2005.

Her research has taken her across the globe, presenting papers at prestigious international conferences in countries like China, France, the Netherlands, and Russia. Her work on thermostable proteases and their resistance to extreme conditions has significant implications for industrial biotechnology, especially in detergent and solvent industries.

One of her notable research projects involved studying the inhibitory effects of silver (Ag) and iron (Fe) colloidal nanoparticles on P. aeruginosa and E. coli growth, presented at the 17th International Conference on Biotechnology and Nanotechnology in Venice, Italy, in 2015. This work highlights her foray into nanotechnology and its biomedical applications, particularly in developing antimicrobial agents.

Accolades and Recognition šŸ…

Throughout her career, Dr. Moradian has gained international recognition for her research contributions. She has been invited to present her work at numerous prestigious conferences, where her findings have been well-received by the global scientific community. Her work on cancer research, particularly the cytotoxic effects of caffeic acid extracted from Echinacea purpurea on human gastric cancer cells, has garnered significant attention. Presented at the International Conference on Medical and Health Sciences in Saint Petersburg, Russia, in 2018, this study underscores her commitment to discovering new avenues for cancer treatment using natural compounds.

Additionally, Dr. Moradian’s research on lactoferrin and its antimicrobial and anticancer effects, which she presented at various conferences in Paris and Indonesia, has positioned her as a key contributor to the field of medical biochemistry, particularly in exploring non-invasive treatments for stomach adenocarcinoma.

Impact and Influence šŸŒ

Dr. Moradian’s contributions have not only advanced scientific knowledge but have also inspired future generations of scientists. Through her teaching and mentorship, she has guided numerous students toward successful careers in biochemistry and biotechnology. Her integration of theoretical knowledge with real-world applications has been particularly influential in shaping her students’ understanding of the critical role biochemistry plays in solving global challenges, from environmental sustainability to cancer treatment.

Her research on thermostable enzymes and antimicrobial nanoparticles continues to have a broad impact on industries ranging from pharmaceuticals to environmental sciences. Additionally, her work on stress responses in plants, particularly the superoxide dismutase activity in salt stress conditions in Aeluropus littoralis, has implications for agricultural biotechnology and improving crop resilience.

Legacy and Future Contributions 🌱

As an established biochemist with a strong research portfolio, Dr. Moradian’s legacy is already well-established in the fields of enzymology, cancer research, and microbial biochemistry. However, her work is far from over. She continues to explore new frontiers in biochemistry, particularly in the areas of cancer therapeutics and environmental biotechnology. With her vast experience and network of international collaborators, Dr. Moradian is poised to make further groundbreaking contributions to science.
Her future projects are expected to delve deeper into understanding the biochemical mechanisms underlying cancer cell resistance and finding novel ways to target them using natural compounds and engineered nanoparticles.

In summary, Dr. Fatemeh Moradian is a biochemist whose career is marked by innovative research, impactful teaching, and a commitment to scientific discovery. Her work continues to inspire and influence both her peers and the next generation of scientists.

šŸŽ“PublicationĀ 

In vitro study of the expression of autophagy genes ATG101, mTOR and AMPK in breast cancer with treatment of lactoferrin and in silico study of their communication networks and protein interact

  • AuthorsĀ  Ā :Atefeh Mashhadi Kholerdi;Ā Fatemeh Moradian;Ā Havva Mehralitabar
  • JournalĀ  Ā  :Biophysics and Molecular Biology
  • YearĀ  Ā  Ā  Ā  Ā :2024

Identification, Isolation, Cloning, and Expression of a New Alkaline Serine Protease Gene from Native Iranian Bacillus sp. RAM 53 for Use in the Industry

  • AuthorsĀ  Ā : Aliakbar Alei;Ā Fatemeh Moradian;Ā Ayoub Farhadi;Ā Mehdi Rostami
  • JournalĀ  Ā  :Applied Biochemistry and Biotechnology
  • YearĀ  Ā  Ā  Ā  Ā :2023

Nanoencapsulation of oral‐pharmaceutical lactoferrin using chitosan and the evaluation of stability against trypsin and pepsin and its antibacterial effect

  • AuthorsĀ  Ā :Ijaz, R., Waqas, M., Mahal, A., Alatawi, N.S., Aloui, Z.
  • JournalĀ  Ā  :Journal of Molecular Graphics and Modelling,
  • YearĀ  Ā  Ā  Ā  Ā :2024

Rational designing of phenothiazine dioxide based hole transporting materials for efficient perovskite solar cells

  • AuthorsĀ  Ā : Farzaneh Hedyeloo;Ā Fatemeh Moradian;Ā Mehran Rostami
  • JournalĀ  Ā  :Micro & Nano Letters
  • YearĀ  Ā  Ā  Ā  Ā :2023

The effect of lactoferrin on ULK1 and ATG13 genes expression in breast cancer cell line MCF7 and bioinformatics studies of protein interaction between lactoferrin and the autophagy initiation complex

  • AuthorsĀ  Ā : Zahra Karabi;Ā Fatemeh Moradian;Ā Mitra Kheirabadi
  • JournalĀ  Ā  :Cell Biochemistry and Biophysics
  • YearĀ  Ā  Ā  Ā  Ā :2022